Literature DB >> 16442195

Community dysfunction in schizophrenia: rate-limiting factors.

Vasilis P Bozikas1, Mary H Kosmidis, Anna Kafantari, Katerina Gamvrula, Eleni Vasiliadou, Petros Petrikis, Kostas Fokas, Athanasios Karavatos.   

Abstract

The purpose of the present study was to investigate the impact of cognitive functioning, psychopathology, and severity of extrapyramidal side effects on community outcome in a group of Greek outpatients with schizophrenia. Participants were 40 outpatients with schizophrenia (25 men). Social adjustment was assessed with the Quality of Life Scale (QLS). Severity of symptoms of schizophrenia was measured with the Positive and Negative Syndrome Scale (PANNS), and extrapyramidal symptoms with the Extrapyramidal Symptom Rating Scale (ESRS). Finally, a battery of neuropsychological tests was administered in order to assess the following cognitive domains: executive functioning/set shifting, executive functioning/inhibition, fluency, verbal memory, visual memory, working memory, attention, visuospatial ability, and psychomotor speed/visual scanning. Total scores on the QLS were significantly correlated with negative symptoms, parkinsonism, and performance on the fluency tasks. Interpersonal relations subscale was significantly related with negative symptoms and fluency. No significant relationship was found between the Instrumental Role Functioning subscale and the PANSS, ESRS, or any cognitive domain. Scores on the Intrapsychic Foundation subscale were significantly correlated with negative symptoms and fluency. Finally, scores on the Common Objects and Activities subscale were significantly related with severity of negative symptoms, parkinsonism and visual memory. Our findings suggest that severity of negative symptoms, cognitive dysfunction, especially performance on fluency tasks and visual memory, as well as parkinsonism, are important determinants of functional outcome in schizophrenia.

Entities:  

Mesh:

Year:  2006        PMID: 16442195     DOI: 10.1016/j.pnpbp.2005.11.017

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum.

Authors:  Margaret M McClure; Philip D Harvey; Marianne Goodman; Joseph Triebwasser; Antonia New; Harold W Koenigsberg; Larry J Sprung; Janine D Flory; Larry J Siever
Journal:  Neuropsychopharmacology       Date:  2010-02-03       Impact factor: 7.853

2.  Predictors of community functioning in schizophrenia and substance use disorder patients.

Authors:  Simon Zhornitsky; Ginette Aubin; Joelle Desfossés; Elie Rizkallah; Tania Pampoulova; Olivier Lipp; Jean-Pierre Chiasson; Emmanuel Stip; Stéphane Potvin
Journal:  Community Ment Health J       Date:  2012-07-31

3.  Insight, quality of life, and functional capacity in middle-aged and older adults with schizophrenia.

Authors:  Ashley S Roseman; John Kasckow; Ian Fellows; Katerine Osatuke; Thomas L Patterson; Somaia Mohamed; Sidney Zisook
Journal:  Int J Geriatr Psychiatry       Date:  2008-07       Impact factor: 3.485

4.  Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis.

Authors:  Joseph Ventura; Gerhard S Hellemann; April D Thames; Vanessa Koellner; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2009-07-22       Impact factor: 4.939

5.  Psychosocial disabilities in patients with schizophrenia.

Authors:  Ma Goreishizadeh; A Mohagheghi; S Farhang; L Alizadeh
Journal:  Iran J Public Health       Date:  2012-05-31       Impact factor: 1.429

6.  Interview-based assessment of cognition is a strong predictor of quality of life in patients with schizophrenia and severe negative symptoms.

Authors:  Breno F Cruz; Camilo B de Resende; Carolina F Carvalhaes; Clareci S Cardoso; Antonio L Teixeira; Richard S Keefe; Fábio L Rocha; João V Salgado
Journal:  Braz J Psychiatry       Date:  2016-06-14       Impact factor: 2.697

7.  Is the GABA System Related to the Social Competence Improvement Effect of Aripiprazole? An (18)F-Fluoroflumazenil PET Study.

Authors:  Jung Suk Lee; Jong Doo Lee; Hae-Jeong Park; Maeng-Keun Oh; Ji Won Chun; Se-Joo Kim; Eosu Kim; Jae-Jin Kim
Journal:  Psychiatry Investig       Date:  2013-01-24       Impact factor: 2.505

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.